Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study
Pavel ME, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, Houchard A, Ruszniewski P (2021)
Publication Type: Conference contribution
Publication year: 2021
Journal
Publisher: LIPPINCOTT WILLIAMS & WILKINS
City/Town: PHILADELPHIA
Pages Range: 448-448
Conference Proceedings Title: PANCREAS
Authors with CRIS profile
Involved external institutions
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
Charité - Universitätsmedizin Berlin
Germany (DE)
University of Warmia and Mazury in Olsztyn
Poland (PL)
Queen Elizabeth Hospital Birmingham
United Kingdom (GB)
Cliniques universitaires Saint-Luc (CHU St-Luc)
Belgium (BE)
Ipsen Pharma
France (FR)
Hôpital Edouard Herriot
France (FR)
France (FR)
Charité - Universitätsmedizin Berlin
Germany (DE)
University of Warmia and Mazury in Olsztyn
Poland (PL)
Queen Elizabeth Hospital Birmingham
United Kingdom (GB)
Cliniques universitaires Saint-Luc (CHU St-Luc)
Belgium (BE)
Ipsen Pharma
France (FR)
Hôpital Edouard Herriot
France (FR)
How to cite
APA:
Pavel, M.E., Cwikla, J., Lombard-Bohas, C., Borbath, I., Shah, T., Pape, U.-F.,... Ruszniewski, P. (2021). Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study. In PANCREAS (pp. 448-448). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
MLA:
Pavel, Marianne Ellen, et al. "Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study." Proceedings of the PANCREAS PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2021. 448-448.
BibTeX: Download